

Audited Full Year Financial Statement And Dividend Announcement For The Year Ended 31 December 2010

PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS

1(a) **An income statement (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year**

Group	2010 S\$'000	2009 S\$'000	Change %
Revenue	239,123	218,610	9.4
Other operating income	3,474	600	479.0
Inventories and consumables used	(26,622)	(24,514)	8.6
Purchased and contracted services	(17,483)	(16,035)	9.0
Staff costs	(115,760)	(104,863)	10.4
Depreciation of property, plant and equipment	(6,935)	(6,891)	0.6
Operating lease expenses	(5,588)	(5,133)	8.9
Other operating expenses	(17,240)	(16,497)	4.5
Profit from operating activities	52,969	45,277	17.0
Finance income	366	180	103.3
Finance expenses	(239)	(410)	(41.7)
Profit before income tax	53,096	45,047	17.9
Income tax expense	(7,614)	(7,014)	8.6
Profit for the year	45,482	38,033	19.6
Attributable to :			
Owners of the Company	45,265	37,882	19.5
Non-controlling interests	217	151	43.7
Profit for the year	45,482	38,033	19.6

1(a) **An income statement (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year (Cont'd)**

	2010	2009	Change
	S\$'000	S\$'000	%
Consolidated statement of comprehensive income			
Profit for the year	45,482	38,033	19.6
Other comprehensive income			
Foreign currency translation differences for foreign operations	374	34	nm
Total comprehensive income for the year	<u>45,856</u>	<u>38,067</u>	20.5
Attributable to:			
Owners of the Company	45,639	37,916	20.4
Non-controlling interests	217	151	43.7
Total comprehensive income for the year	<u>45,856</u>	<u>38,067</u>	20.5

Explanatory notes to the income statement

- Staff costs increased in tandem with higher volume of business in the Group. Excluding the jobs credit grants received by the Group, the rate of increase for staff costs would have grown by 7.5% in 2010.
- Profit from ordinary activities before taxation includes the following:

Group	2010	2009
	S\$'000	S\$'000
(a) Other operating income		
Gain on disposal of property, plant and equipment	474	-
Change in fair value in investment properties	3,000	600
(b) Other operating expenses		
Allowance for doubtful receivables	1,194	1,112
Amortisation of intangible assets	51	52
Property, plant and equipment written-off	31	46

- The adjustment for under and over-provision of tax in respect of prior years are as follows:

Group	2010	2009
	S\$'000	S\$'000
Deferred tax expense		
Under provision in respect of prior years	22	88
Current tax expense		
Under/(Over) provision in respect of prior years	8	(267)

RafflesMedicalGroup

1(b)(i) A balance sheet (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

	Group		Company	
	2010 S\$'000	2009 S\$'000	2010 S\$'000	2009 S\$'000
Non-current assets				
Property, plant and equipment	144,253	146,435	3,252	3,527
Intangible assets	316	367	245	245
Investment properties	88,000	85,000	-	-
Subsidiaries	-	-	202,881	197,582
Deferred tax assets	895	528	-	-
	<u>233,464</u>	<u>232,330</u>	<u>206,378</u>	<u>201,354</u>
Current assets				
Inventories	5,083	5,273	1,258	1,711
Trade and other receivables	26,066	24,283	18,251	15,695
Cash and cash equivalents	107,137	74,372	88,664	59,087
Assets classified as held for sale	-	553	-	-
	<u>138,286</u>	<u>104,481</u>	<u>108,173</u>	<u>76,493</u>
Total assets	<u>371,750</u>	<u>336,811</u>	<u>314,551</u>	<u>277,847</u>
Equity attributable to owners of the Company				
Share capital	177,006	172,659	177,006	172,659
Reserves	109,414	77,114	55,955	38,064
	<u>286,420</u>	<u>249,773</u>	<u>232,961</u>	<u>210,723</u>
Non-controlling interests	542	377	-	-
Total equity	<u>286,962</u>	<u>250,150</u>	<u>232,961</u>	<u>210,723</u>
Non-current liabilities				
Deferred tax liabilities	1,690	1,439	402	209
Interest-bearing liabilities	18,000	20,000	-	-
	<u>19,690</u>	<u>21,439</u>	<u>402</u>	<u>209</u>
Current liabilities				
Trade and other payables	50,972	51,972	76,905	62,757
Interest-bearing liabilities	4,577	4,519	2,577	2,236
Current tax payable	9,549	8,731	1,706	1,922
	<u>65,098</u>	<u>65,222</u>	<u>81,188</u>	<u>66,915</u>
Total liabilities	<u>84,788</u>	<u>86,661</u>	<u>81,590</u>	<u>67,124</u>
Total equity and liabilities	<u>371,750</u>	<u>336,811</u>	<u>314,551</u>	<u>277,847</u>

Explanatory notes to the Balance Sheet

1. Strong operating cashflows generated by the Group in line with higher volume of business in the Group have resulted in improvements in net cash position of S\$84.6 million as at 31 December 2010 as compared to that of S\$49.9 million as at 31 December 2009.
2. Trade and other receivables increased in tandem with higher volume of business in the Group.

1(b)(ii) Aggregate amount of group's borrowings and debt securities.

Amount repayable in one year or less, or on demand

As at 31/12/2010		As at 31/12/2009	
Secured	Unsecured	Secured	Unsecured
S\$0	S\$4,577,113	S\$0	S\$4,518,758

Amount repayable after one year

As at 31/12/2010		As at 31/12/2009	
Secured	Unsecured	Secured	Unsecured
S\$0	S\$18,000,000	S\$0	S\$20,000,000

Details of any collateral

Nil.

RafflesMedicalGroup

1(c) A cash flow statement (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

	2010	2009
	S\$'000	S\$'000
Cash flows from operating activities		
Profit before income tax	53,096	45,047
Adjustments for :-		
Amortisation of intangible assets	51	52
Depreciation of property, plant and equipment	6,935	6,891
Equity-settled share-based payment transactions	2,359	1,585
Finance expenses	239	410
Gain on disposal of property, plant and equipment	(474)	-
Interest income from fixed deposits	(366)	(180)
Property, plant and equipment written off	31	46
Revaluation gain of investment properties	(3,000)	(600)
Operating profit before working capital changes	<u>58,871</u>	<u>53,251</u>
Changes in working capital :-		
Inventories	190	(523)
Trade and other receivables	(1,816)	802
Trade and other payables	(883)	318
Cash generated from operations	<u>56,362</u>	<u>53,848</u>
Income taxes paid	(6,913)	(6,229)
Interest paid	(239)	(410)
Net cash from operating activities	<u>49,210</u>	<u>47,209</u>
Cash flows from investing activities		
Interest received	399	180
Proceeds from sale of property, plant and equipment	1,661	206
Purchase of property, plant and equipment	(5,452)	(3,892)
Net cash used in investing activities	<u>(3,392)</u>	<u>(3,506)</u>
Cash flows from financing activities		
Dividends paid	(15,698)	(12,965)
Dividends paid to non-controlling shareholder of the subsidiary	(52)	(35)
Proceeds from issue of shares under share option scheme	4,347	1,312
Proceeds from bank loan	6,870	3,129
Repayment of bank loan	(8,220)	(5,127)
Repayment of loan to non-controlling shareholder	-	(60)
Net cash used in financing activities	<u>(12,753)</u>	<u>(13,746)</u>
Net increase in cash and cash equivalents	33,065	29,957
Cash and cash equivalents at 1 January	74,089	44,121
Effect of exchange rate changes on balances held in foreign currency	(17)	11
Cash and cash equivalents at 31 December	<u>107,137</u>	<u>74,089</u>
Cash and cash equivalents at end of the year include the following :		
Cash & fixed deposits	107,137	74,372
Bank overdrafts	-	(283)
	<u>107,137</u>	<u>74,089</u>

RafflesMedicalGroup

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Group	Share capital S\$'000	Currency translation reserve S\$'000	Share option reserve S\$'000	Accumulated profits S\$'000	Total attributable to owners of the Company S\$'000	Non-controlling interests S\$'000	Total equity S\$'000
At 1 January 2009	171,347	(355)	3,837	47,096	221,925	321	222,246
Comprehensive income for the year							
Profit for the year	-	-	-	37,882	37,882	151	38,033
Other comprehensive income							
Foreign currency translation differences for foreign operations	-	34	-	-	34	-	34
Total comprehensive income for the year	-	34	-	37,882	37,916	151	38,067
Transactions with owners, recorded directly in equity							
Contributions by and distributions to owners							
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	1,312	-	-	-	1,312	-	1,312
Value of employee services received for issue of share options	-	-	1,585	-	1,585	-	1,585
Final dividend paid of 1.5 cents per ordinary share	-	-	-	(7,777)	(7,777)	-	(7,777)
Interim dividend paid of 1.0 cent per ordinary share	-	-	-	(5,188)	(5,188)	-	(5,188)
Repayment of loan to non-controlling shareholder	-	-	-	-	-	(60)	(60)
Dividends distributed to non-controlling shareholder	-	-	-	-	-	(35)	(35)
Total contributions by and distributions to owners	1,312	-	1,585	(12,965)	(10,068)	(95)	(10,163)
At 31 December 2009	172,659	(321)	5,422	72,013	249,773	377	250,150
At 1 January 2010	172,659	(321)	5,422	72,013	249,773	377	250,150
Comprehensive income for the year							
Profit for the year	-	-	-	45,265	45,265	217	45,482
Other comprehensive income							
Foreign currency translation differences for foreign operations	-	374	-	-	374	-	374
Total comprehensive income for the year	-	374	-	45,265	45,639	217	45,856
Transactions with owners, recorded directly in equity							
Contributions by and distributions to owners							
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	4,347	-	-	-	4,347	-	4,347
Value of employee services received for issue of share options	-	-	2,359	-	2,359	-	2,359
Final dividend paid of 2.0 cents per ordinary share	-	-	-	(10,452)	(10,452)	-	(10,452)
Interim dividend paid of 1.0 cent per ordinary share	-	-	-	(5,246)	(5,246)	-	(5,246)
Dividends distributed to non-controlling shareholder	-	-	-	-	-	(52)	(52)
Total contributions by and distributions to owners	4,347	-	2,359	(15,698)	(8,992)	(52)	(9,044)
At 31 December 2010	177,006	53	7,781	101,580	286,420	542	286,962

RafflesMedicalGroup

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year (Cont'd).

Company	Share capital S\$'000	Share option reserve S\$'000	Accumulated profits S\$'000	Total S\$'000
At 1 January 2009	171,347	3,837	21,474	196,658
Comprehensive income for the year				
Profit for the year	-	-	24,133	24,133
Total comprehensive income for the year	-	-	24,133	24,133
Transactions with owners, recorded directly in equity				
Contributions by and distributions to owners				
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	1,312	-	-	1,312
Value of employee services received for issue of share options	-	1,585	-	1,585
Final dividend paid of 1.5 cents per ordinary share	-	-	(7,777)	(7,777)
Interim dividend paid of 1.0 cent per ordinary share	-	-	(5,188)	(5,188)
Total contributions by and distributions to owners	1,312	1,585	(12,965)	(10,068)
At 31 December 2009	172,659	5,422	32,642	210,723
At 1 January 2010	172,659	5,422	32,642	210,723
Comprehensive income for the year				
Profit for the year	-	-	31,230	31,230
Total comprehensive income for the year	-	-	31,230	31,230
Transactions with owners, recorded directly in equity				
Contributions by and distributions to owners				
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	4,347	-	-	4,347
Value of employee services received for issue of share options	-	2,359	-	2,359
Final dividend paid of 2.0 cents per ordinary share	-	-	(10,452)	(10,452)
Interim dividend paid of 1.0 cent per ordinary share	-	-	(5,246)	(5,246)
Total contributions by and distributions to owners	4,347	2,359	(15,698)	(8,992)
At 31 December 2010	177,006	7,781	48,174	232,961

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles, as well as the number of shares held as treasury shares, if any, against the total number of issued shares excluding treasury shares of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

During the year ended 31 December 2010, the Company issued 5,984,000 new shares, upon the exercise of options under the Raffles Medical Group (2000) Share Option Scheme.

Exercise price per share	S\$0.185	S\$0.23	S\$0.32	S\$0.33	S\$0.40	S\$0.42
Number of new shares issued	210,000	110,000	393,000	407,000	100,000	675,000

Exercise price per share	S\$0.68	S\$0.71	S\$0.78	S\$1.14	S\$1.15	S\$1.24
Number of new shares issued	100,000	776,000	1,826,000	20,000	685,000	682,000

On 1 April 2010, options to subscribe for 6,000,000 ordinary shares at an exercise price of S\$1.66 were granted to 399 eligible participants pursuant to the Raffles Medical Group (2000) Share Option Scheme.

As at 31 December 2010, there were outstanding options for conversion into 19,894,000 (2009 : 20,960,000) ordinary shares.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at end of the immediately preceding year.

	31/12/2010	31/12/2009
Number of issued shares excluding treasury shares	525,944,393	519,960,393

1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

There were no sales, transfers, disposal, cancellation and/or use of treasury shares as at 31 December 2010 (31 December 2009 : Nil).

2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The financial statements on consolidated results for the year ended 31 December 2010 have been audited in accordance with Singapore Standards on Auditing.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

As per attached.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

Accounting policies and methods of computation used in the consolidated financial statements for the year ended 31 December 2010 are consistent with those applied in the financial statements for the year ended 31 December 2009, except for the adoption of accounting standards (including its consequential amendments) and interpretations applicable for the financial period beginning 1 January 2010. The adoption of the new/revised accounting standards and interpretations does not have any material impact on the financial statements of the Group.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

Please refer to Item 4 above.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

	2010	2009
Earnings per ordinary share for the period based on 1(a) above :-		
(i) Basic earnings per share [A]	8.65 cents	7.30 cents
(ii) Diluted earnings per share [B]	8.51 cents	7.22 cents

[A] The calculations of earnings per ordinary share is based on weighted average number of shares of 523,267,127 (2009 : 518,730,618) in issue during the year.

[B] The calculations of earnings per ordinary share (on a fully diluted basis) is based on weighted average number of shares of 531,752,618 (2009 : 524,365,827) in issue during the year.

7. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:-

- (a) current financial period reported on; and
- (b) immediately preceding financial year.

	Group		Company	
	31/12/2010	31/12/2009	31/12/2010	31/12/2009
Net asset value per ordinary share [C]	54.46 cents	48.04 cents	44.29 cents	40.53 cents

[C] The calculation of net asset value per ordinary share is based on 525,944,393 shares as at 31 December 2010 (31 December 2009 : 519,960,393).

RafflesMedicalGroup

8. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-**
- (a) **any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**
 - (b) **any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

The Group's revenue for 2010 attained a record of **S\$239.1** million, an increase of **9.4%** from **S\$218.6** million in 2009. All divisions of the Group continued to contribute positively to the growth in revenue. Revenue of Hospital Services and Healthcare Services divisions increased **12.1%** and **6.1%** respectively.

Profit from operating activities increased by **17.0%** from **S\$45.3** million in 2009 to **S\$53.0** million in 2010. Higher patient load, wider range of medical specialties, continued improved operating efficiencies and the recruitment of more specialist consultants contributed to the improved performance.

The Group's profit after tax grew **19.6%** from **S\$38.0** million in 2009 to **S\$45.5** million in 2010 in line with better operating performance and leverage. Excluding the impact of jobs credit grants received by the Group and revaluation gains of investment property in 2009 and 2010, profit after tax for 2010 would have grown by **22.9%**.

The Group had a healthy net cash position of **S\$84.6** million as at 31 December 2010, from the continued strong operating cashflows generated by the Group after distributing dividends of **S\$15.7** million in 2010. The strong cash position will enable the Group to fund its growth.

9. **Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

The current financial year's results are in line with the Directors' expectations as disclosed in the Group's Q3 2010 results announcement.

10. **A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

The outlook for the global economic environment has improved. However, risks remain with the Eurozone debt concerns and the uneven recovery of the United States, with its continuing high unemployment. The regional economies continue to perform well, with Singapore registering robust GDP growth of 14.5% for 2010. The Group expects to continue to benefit from the growing demand for high quality healthcare services locally and from the region, on the back of rising affluence and the aging population.

RafflesHospital will continue its focus on quality and value-driven curative healthcare services. Foreign patient load continues to increase. With its well-diversified foreign patient base and growth in specialist staff and competencies, the hospital is expected to continue to perform well and contribute positively to the Group's performance.

The architectural consultants are finalizing the design scheme for the 102,408 square feet expansion of **RafflesHospital** and liaising with the authorities on the relevant submissions. It is expected that construction should commence in the second half of this year. This additional area will enable the Group to expand existing clinical services as well as to develop new facilities and services at the hospital.

RafflesMedicalGroup

10. **A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months (Cont'd).**

The Group had successfully tendered for the 7 storey freehold podium/commercial block of Thong Sia Building (Property) at 30 Bideford Road in Singapore for a purchase consideration of S\$92.08 million. The Group intends to establish a Specialist Medical Centre at the Property. When fully established, the Centre would have the following services and facilities: A 24-hour Emergency Care Centre, Health Screening Centre, Radiology and Imaging Centre, Medical Laboratory, Fertility Centre, Cancer Centre, Dental Centre and clinics for Obstetrics and Gynaecology, Paediatrics, Cardiology, General Surgery, Orthopaedic Surgery, Ophthalmology, ENT Surgery, Dermatology and Medical Aesthetics. The purchase is expected to be completed by end April 2011 and will be financed with a combination of internal funds and bank borrowings.

RafflesMedical will also continue to contribute to the Group's performance, through the provision of comprehensive services and cost-effective solutions to the growing group of corporate clients and individual patients.

The healthcare landscape remains competitive, with additional beds of new public and private hospitals coming onstream over the next few years. Whilst adding more space to **RafflesHospital**, the Group continues to be vigilant and responsive to new opportunities that may appear on the horizon.

Barring unforeseen circumstances, the Directors are optimistic that the Group will continue to grow in 2011.

11. Dividend

(a) Current Financial Period Reported On

Any dividend declared for the current financial period reported on? Yes

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	1.0 cent per ordinary share (one tier tax)
Tax Rate	Tax Exempt

Name of Dividend	Final
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	2.5 cents per ordinary share (one tier tax)
Tax Rate	Tax Exempt

11. Dividend (Cont'd)

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year? Yes

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	1.0 cent per ordinary share (one tier tax)
Tax Rate	Tax Exempt

Name of Dividend	Final
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	2.0 cents per ordinary share (one tier tax)
Tax Rate	Tax Exempt

(c) Date payable

The Directors are pleased to recommend a final dividend of 2.5 cents per share in respect of the financial year ended 31 December 2010 for approval by the shareholders at the next Annual General Meeting to be convened on 29 April 2011. Including the interim net dividend of 1 cent per share paid in September 2010, total dividends for financial year ended 31 December 2010 would amount to 3.5 cents per share, an increase of 0.5 cent (16.7%) as compared to financial year ended 31 December 2009.

The date of payment of the proposed dividends, if approved at the Annual General Meeting, will be announced at a later date.

(d) Books closure date

The books closure date will be announced at a later date.

(e) Scrip dividend scheme

The Scrip Dividend Scheme will be applicable to the final dividend. The issue price of a new share shall not be set at more than 10% discount to, nor shall it exceed the average of the last dealt prices of a share on the SGX-ST for each of the market days during the price determination period (being the period commencing on the day on which the shares are first quoted ex-dividend and ending on the books closure date to determine the entitlements to the final dividend). Further details will be announced at a later date.

12. If no dividend has been declared/recommended, a statement to that effect.

Not applicable.

PART II - ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT

(This part is not applicable to Q1, Q2, Q3 or Half Year Results)

13. Segmented revenue and results for business or geographical segments (of the group) in the form presented in the issuer's most recently audited annual financial statements, with comparative information for the immediately preceding year

13.(a) Business Segments

	Healthcare services S\$'000	Hospital services S\$'000	Investment holdings S\$'000	Total S\$'000
2010				
Revenue and expenses				
External revenue	94,864	154,575	7,940	257,379
Inter-segment revenue	1,357	9,088	7,811	18,256
Finance expenses	(31)	-	(208)	(239)
Depreciation of property, plant and equipment	(1,701)	(2,797)	(165)	(4,663)
Amortisation of intangible assets	-	-	(51)	(51)
Reportable segment profit before income tax	8,257	38,502	8,609	55,368
Reportable segment assets	322,103	88,964	346,379	757,446
Capital expenditure	1,410	4,042	-	5,452
Reportable segment liabilities	97,038	43,081	196,740	336,859
	Healthcare services S\$'000	Hospital services S\$'000	Investment holdings S\$'000	Total S\$'000
2009				
Revenue and expenses				
External revenue	89,382	137,899	7,799	235,080
Inter-segment revenue	685	8,137	7,648	16,470
Finance expenses	(59)	-	(351)	(410)
Depreciation of property, plant and equipment	(1,627)	(2,802)	(190)	(4,619)
Amortisation of intangible assets	-	-	(52)	(52)
Reportable segment profit before income tax	6,902	34,075	6,342	47,319
Reportable segment assets	296,761	72,276	347,713	716,750
Capital expenditure	1,864	2,028	-	3,892
Reportable segment liabilities	83,271	35,387	199,567	318,225

13.(a) Business Segments (cont'd)

Reconciliations of reportable segment revenues, profit or loss, assets and liabilities and other material items

	2010 S\$'000	2009 S\$'000
Revenues		
Total revenue for reportable segments	257,379	235,080
Elimination of inter-segment revenue	(18,256)	(16,470)
Consolidated revenue	<u>239,123</u>	<u>218,610</u>
Profit or loss		
Total profit for reportable segments	55,368	47,319
Adjustment for depreciation of property, plant and equipment	(2,272)	(2,272)
Consolidated profit before income tax	<u>53,096</u>	<u>45,047</u>
Assets		
Total assets for reportable segments	757,446	716,750
Elimination of inter-segment assets	(386,591)	(380,467)
Unallocated amounts – deferred tax assets	895	528
Consolidated total assets	<u>371,750</u>	<u>336,811</u>
Liabilities		
Total liabilities for reportable segments	336,859	318,225
Elimination of inter-segment liabilities	(263,310)	(241,734)
Unallocated amounts – current and deferred tax liabilities	11,239	10,170
Consolidated total liabilities	<u>84,788</u>	<u>86,661</u>

Other material items

	Reportable segment totals S\$'000	Adjustments S\$'000	Consolidated totals S\$'000
2010			
Depreciation of property, plant and equipment	4,663	2,272	<u>6,935</u>
2009			
Depreciation of property, plant and equipment	4,619	2,272	<u>6,891</u>

The hospital building at North Bridge Road is owned by a subsidiary and classified as Investment Property in the subsidiary's standalone financial statements. In accordance with the Group's accounting policies, investment property is measured at fair value and not depreciated.

For the preparation of the consolidated financial statements, the hospital building is reclassified from Investment Property to Property, Plant and Equipment as the building is used in the supply of hospital services by the Group. Accordingly, the carrying value of the hospital building is depreciated over its useful life in the consolidated financial statements of the Group.

The amount of \$2,272,000 (2009: \$2,272,000) relates to the depreciation of the hospital building for the year ended 31 December 2010.

14. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments.

Please refer to Item 8.

15. A breakdown of sales.

		Group		
		2010 S\$'000	2009 S\$'000	Change %
15(a)	Revenue reported for first half	114,772	104,926	9.4
15(b)	Operating profit after tax before deducting minority interests reported for first half year	19,724	16,638	18.5
15(c)	Revenue reported for second half	124,351	113,684	9.4
15(d)	Operating profit after tax before deducting minority interests reported for second half year	25,758	21,395	20.4

16. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year.

	2010 S\$'000	2009 S\$'000
Ordinary	15,698	12,965
Preference	0	0
Total	15,698	12,965

BY ORDER OF THE BOARD

Tay Kim Choon Kimmy
Company Secretary
21 February 2011